ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – an EAACI-ARIA Position Paper

Ludger Klimek1, Marek Jutel2, Cezmi Akdis3, Jean Bousquet4, Mubeccel Akdis5, María José Torres6, Ioana Agache7, Giorgio Walter Canonica8, Stefano R. Del Giacco9, Liam O’Mahony10, Mohamed Shamji11, Ruby Pawankar12, Eva Untersmayr13, Johannes Ring14, Anna Bedbrook15, Margitta Worm16, and Torsten Zuberbier17

1Zentrum für Rhinologie und Allergologie
2Wroclaw Medical University
3University of Zurich
4Université Versailles, St-Quentin-en-Yvelines
5University of Zürich
6Universidad de Málaga Facultad de Medicina
7Transylvania University of Brasov
8Humanitas Clinical and Research Center
9University of Cagliari Faculty of Medicine
10University College Cork National University of Ireland
11Imperial College London
12Nippon Medical School
13Center of Physiology, Pathophysiology and Immunology
14Technische Universität München
15Hôpital Arnaud de Villeneuve
16Charité - Universitätsmedizin Berlin
17Charité Universitätsmedizin Berlin

December 28, 2020

Abstract

Coronavirus disease 2019 (COVID-19) vaccine BNT162b2 received approval and within the first few days of public vaccination several severe anaphylaxis cases occurred. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and concerns raised for severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerges. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as the exclusion of all these patients from vaccination may have a significant impact on reaching the goal of population immunity. Health care practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognise and treat anaphylaxis properly with the ability to administer adrenaline. A mandatory observation period after vaccine administration of at least 15 minutes for all individuals should be followed. The current guidelines, which exclude patients with severe allergies from vaccination with BNT162b2, should be re-evaluated after more information and experience.
with the new vaccine develops.

Hosted file